Semaglutide May Delay Kidney Disease Progression Recent Trial Findings Reveal

Can semaglutide delay kidney disease progression, and what do recent trial findings show in Europe?Semaglutide and kidney disease explained: GLP-1 receptor agonist therapy, chronic kidney disease (CKD), albuminuria reduction, cardiovascular risk, and prescribing criteria.In this episode, we review emerging trial data suggesting semaglutide may slow progression of chronic kidney disease in certain patients, and how doctors interpret these findings under EU medical guidance.You’ll learn:• What semaglutide is and how GLP-1 receptor agonists work• The link between type 2 diabetes and chronic kidney disease• How improved glycaemic control may reduce kidney strain• Evidence on albuminuria reduction and renal outcomes• The difference between slowing progression and reversing kidney damage• Monitoring requirements: eGFR, urine albumin, blood pressure• Situations where treatment initiation may be declined pending renal assessmentWe explain how doctors assess HbA1c, eGFR, urine albumin-to-creatinine ratio, blood pressure, cardiovascular risk, and existing kidney function during an online consultation in the EU. Semaglutide is prescribed based on approved metabolic indications, not solely for renal protection.This episode reflects the clinical standards used by Mobi Doctor, where metabolic and renal risk consultations are reviewed by a registered physician in line with EU prescribing guidance.Read the full guide and transcript here:https://www.mobidoctor.eu/blog/semaglutide-may-delay-kidney-disease-progression-recent-trial-findings-reveal